Raymond James Financial
BEAM icon

Raymond James Financial’s Beam Therapeutics BEAM Stock Holding History

Raymond James Financial’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
38,746
+6,183
+19% +$187K ﹤0.01% 3784
2026
Q1 		$776K Buy
32,563
+4,448
+16% +$123K ﹤0.01% 4046
2025
Q4 		$779K Buy
28,115
+788
+3% +$20.1K ﹤0.01% 3952
2025
Q3 		$663K Buy
27,327
+5,442
+25% +$108K ﹤0.01% 3945
2025
Q2 		$372K Sell
21,885
-4,421
-17% -$77K ﹤0.01% 4176
2025
Q1 		$514K Sell
26,306
-2,022
-7% -$53K ﹤0.01% 3927
2024
Q4 		$703K Buy
+28,328
New +$723K ﹤0.01% 3689

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Raymond James Financial's BEAM Position: Q2 2026 in Review

Raymond James Financial increased its Beam Therapeutics (BEAM) stake by 19% in Q2 2026, buying an estimated $187K and bringing the position to 38,746 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3784.

Raymond James Financial first reported a position in BEAM in Q4 2024 and has held it in 7 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Raymond James Financial held 38,746 shares of Beam Therapeutics worth $1.33M as of Q2 2026.
  • Raymond James Financial bought 6,183 Beam Therapeutics shares in Q2 2026, an estimated $187K.
  • Beam Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3784 holding.
  • Raymond James Financial first reported a position in Beam Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.